Classification of glioblastoma multiforme in adults by molecular genetics

The Cancer Journal
Ramsis BenjaminAlice Brown

Abstract

Recent advances in cytogenetic and molecular methodologies have elucidated certain principal characteristics of oncogenesis in glioblastoma multiforme. The earliest clues implicate gene sequence alterations, such as gene amplification and numerical gain or loss of function in specific chromosomes. Genetic classification and expression patterns have thus been constructed, conferring the likelihood of two types of glioblastoma, primary (de novo) as opposed to secondary (evolving from a pre-existing low-grade glioma). The former group of tumors exhibits more frequent occurrences of EGFR gene amplification, whereas the latter group relies strongly on TP53 gene inactivation. Many other tumor suppressor genes and oncogenes have been discovered. Most gene alterations induce cell cycle dysfunction on a complex molecular level. Further insight into tumor genesis by means of genomic assays may aid in predicting the clinical behavior of glioblastoma and in providing individualized potential targets for therapeutic agents.

References

Jan 1, 1979·Annual Review of Biochemistry·G Carpenter, S Cohen
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A J WongB Vogelstein
Oct 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A J WongB Vogelstein
Aug 1, 1983·Cancer Genetics and Cytogenetics·S Pittman, D Catovsky
Oct 1, 1995·Trends in Genetics : TIG·D N Louis, J F Gusella
Jun 1, 1995·Chromosome Research : an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology·E L MitchellJ Heighway
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·R NishikawaH J Huang
Nov 1, 1995·Glia·V P Collins
Mar 1, 1996·International Journal of Radiation Oncology, Biology, Physics·A ZhuA M El-Mahdi
May 3, 1996·International Journal of Cancer. Journal International Du Cancer·K SatoH Ohgaki
Mar 1, 1996·Journal of Neuro-oncology·M MoritaM R Rosenfeld
Oct 1, 1996·Journal of Neuropathology and Experimental Neurology·Y OnoD N Louis
Nov 8, 1996·Science·M R Emmert-BuckL A Liotta
Jun 10, 1998·Oncogene·E M DuerrA von Deimling
Jun 27, 1998·Pathology·H K Ng, P Y Lam
Aug 5, 1998·Journal of Neuropathology and Experimental Neurology·Y TohmaH Ohgaki
Oct 17, 1998·Journal of the National Cancer Institute·J G CairncrossD N Louis
Mar 5, 1999·Cellular and Molecular Life Sciences : CMLS·D A FreedmanA J Levine
May 18, 1999·Current Opinion in Oncology·B K RasheedD D Bigner
Nov 5, 1999·Journal of the National Cancer Institute·M TamuraK M Yamada
Mar 31, 2000·Nature Medicine·S BenedettiG Finocchiaro
Jun 13, 2000·Journal of Neuropathology and Experimental Neurology·M NakamuraH Ohgaki
Mar 21, 2001·Human Molecular Genetics·P Y Lam, X O Breakefield
Mar 27, 2001·Nature Reviews. Genetics·L Liotta, E Petricoin
May 1, 2001·Pathology International·H HoriguchiT Hirose
May 18, 2001·Acta Neuropathologica·C WalkerM L Rossi
Aug 16, 2001·Journal of the National Cancer Institute·J S SmithR B Jenkins
Sep 8, 2001·Progress in Brain Research·P TuniciG Finocchiaro
Sep 11, 2001·The American Journal of Pathology·D N LouisJ G Cairncross
Apr 10, 2002·Journal of Neuropathology and Experimental Neurology·Matthias C SchmidtAndreas von Deimling
Aug 14, 2002·Cancer·Ahmed RasheedRoger E McLendon

❮ Previous
Next ❯

Citations

Aug 1, 2009·Journal of Neuro-oncology·Ramon MartinezGabriele Schackert
Apr 16, 2009·Cancer Research·Elaine L BearerVittorio Cristini
May 24, 2011·Molecular Cancer·Masanao TabuseMasahiro Toda
Oct 4, 2012·Journal of Medical Case Reports·Moulay Rachid El El MaaqiliFouad Bellakhdar
Mar 26, 2009·Acta neurochirurgica·Gordan GrahovacMario Habek
Feb 24, 2016·Biochemical and Biophysical Research Communications·Jia LiChanglin Zou
Jul 22, 2014·Expert Opinion on Therapeutic Targets·Er-Bao BianBing Zhao
Jun 9, 2006·Expert Review of Anticancer Therapy·Florence LefrancRobert Kiss
Mar 21, 2007·Expert Opinion on Investigational Drugs·David E Gerber, John Laterra
Mar 23, 2010·Journal of Theoretical Biology·Hermann B FrieboesVittorio Cristini
Jan 13, 2010·Neurobiology of Disease·Ramon Martinez, Manel Esteller
May 26, 2009·Seminars in Radiation Oncology·Shin-ei NodaArnab Chakravarti
Jan 5, 2006·Brain Pathology·Jean-Pierre GagnerDavid Zagzag
Jun 26, 2004·Journal of the American College of Surgeons·M Sean Grady
Jan 24, 2006·Surgical Neurology·Clovis Orlando da FonsecaCerli Rocha Gattass
Aug 2, 2011·Journal of Chemotherapy·N H RekersG J Peters
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Florence LefrancRobert Kiss
Jan 15, 2013·EURASIP Journal on Bioinformatics & Systems Biology·Wenlong TangYu-Ping Wang
May 17, 2006·Technology in Cancer Research & Treatment·Peiyu PuHao Jiang
Oct 23, 2004·International Journal of Cancer. Journal International Du Cancer·Dana E M RollisonEugene O Major
Feb 8, 2006·The Journal of Pathology·R Abdel-FattahI M Hussaini
Feb 7, 2020·NPJ Genomic Medicine·Fawz S AlHarthiMalak Abedalthagafi
Feb 13, 2016·Oncology Letters·Yun-Bao GuoHai-Yan Liu
Oct 12, 2018·Cell Death & Disease·Kui ZhangHongjuan Cui
Feb 3, 2021·NPJ Genomic Medicine·Fawz S AlHarthiMalak Abedalthagafi
Jun 15, 2005·Journal of Proteome Research·Federico OdremanAlessandro Vindigni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.